Market Place
Sourcing Support
Clinical Review of Pegylated Interferons Suggests Formulation
21 Feb 2024 //
BUSINESSWIRE
Presentations at MPN Congress Reinforce Role of ropeginterferon alfa-2b-njft
02 Nov 2023 //
BUSINESSWIRE
Ropeginterferon Alfa-2b Produces Responses,Safety in Prefibrotic P Myelofibrosis
30 Jun 2023 //
ONCLIVE
PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi
02 Jun 2023 //
BUSINESSWIRE
AOP Health: Completed Study Strengthens Development for ropeginterferon alpha 2b
01 Jun 2023 //
BUSINESSWIRE
NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi
23 May 2023 //
BUSINESSWIRE
PharmaEssentia takes Besremi rare blood cancer message to consumers
22 Feb 2023 //
ENDPTS
AOP Health presents latest updates on BESREMi in Polycythaemia Vera at ASH
13 Dec 2022 //
BUSINESSWIRE
New Ropeginterferon alfa-2b Data Show Importance of Proactive Care
12 Dec 2022 //
BUSINESSWIRE
Presentations on Ropeginterferon Alfa-2b Highlight Momentum in Polycythemia Vera
03 Nov 2022 //
BUSINESSWIRE
AOP Health Presents Final Results From Its CONTINUATION-PV Study
20 Jun 2022 //
BUSINESSWIRE
NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi
02 Mar 2022 //
BUSINESSWIRE
German Federal Court of Justice Upholds AOP`s License Rights in Ropeginterferon
15 Feb 2022 //
BUSINESSWIRE
U.S. FDA Approves BESREMi for Adults With Polycythemia Vera
14 Nov 2021 //
BUSINESSWIRE
US FDA approves Biogen’s Plegridy to treat multiple sclerosis
02 Feb 2021 //
PHARMABIZ
PharmaEssentia Initiates Pivotal Trial of Ropeginterferon alfa-2b
07 Jan 2021 //
BUSINESSWIRE
AOP Orphan announces five-year results on BESREMi®
07 Dec 2020 //
PRESS RELEASE
Five-Year Data on Ropeginterferon Alfa-2b Illustrate Durable Response
07 Dec 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.